Ken Griffin Kezar Life Sciences, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.53 - $0.77 $53 - $77	-100 Reduced 14.29%	600 $0
Q2 2024 Aug 14, 2024	BUY	$0.6 - $0.92 $60 - $92	100 Added 16.67%	700 $0
Q1 2024 May 15, 2024	SELL	$0.8 - $1.05 $160 - $210	-200 Reduced 25.0%	600 $0
Q4 2023 Feb 14, 2024	SELL	$0.72 - $1.15 $20,592 - $32,890	-28,600 Reduced 97.28%	800 $0
Q3 2023 Nov 14, 2023	SELL	$1.08 - $2.54 $5,832 - $13,716	-5,400 Reduced 15.52%	29,400 $34,000
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $62,832 - $83,232	27,200 Added 357.89%	34,800 $85,000
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $20,971 - $48,977	6,700 Added 744.44%	7,600 $23,000
Q4 2022 Feb 14, 2023	SELL	$6.39 - $8.8 $136,107 - $187,440	-21,300 Reduced 95.95%	900 $6,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $930,036 - $1.25 Million	-116,400 Reduced 83.98%	22,200 $191,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $506M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.